355 related articles for article (PubMed ID: 17177909)
41. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
42. Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma.
Palumbo A; Boccadoro M; Bruno B; Triolo S; Pileri A
Haematologica; 1994; 79(6):513-8. PubMed ID: 7534745
[TBL] [Abstract][Full Text] [Related]
43. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA
J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
[TBL] [Abstract][Full Text] [Related]
44. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Alliot C
J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
[No Abstract] [Full Text] [Related]
45. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
46. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
[TBL] [Abstract][Full Text] [Related]
47. A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients.
Shikama N; Oguchi M; Isobe K; Nakamura K; Tamaki Y; Hasegawa M; Kodaira T; Sasaki S; Kagami Y;
Jpn J Clin Oncol; 2011 Jun; 41(6):764-9. PubMed ID: 21459892
[TBL] [Abstract][Full Text] [Related]
48. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
[TBL] [Abstract][Full Text] [Related]
49. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
[TBL] [Abstract][Full Text] [Related]
50. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
[TBL] [Abstract][Full Text] [Related]
51. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
[TBL] [Abstract][Full Text] [Related]
52. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
[TBL] [Abstract][Full Text] [Related]
53. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma.
Itoh K; Ohtsu T; Wakita H; Igarashi T; Ishizawa K; Onozawa Y; Fujii H; Minami H; Sasaki Y
Ann Oncol; 2000 Oct; 11(10):1241-7. PubMed ID: 11106111
[TBL] [Abstract][Full Text] [Related]
54. [Effect of granulocyte colony-stimulating factor after chemotherapy with CHOP in patients with non-Hodgkin's lymphoma and HIV infection].
Navarro JT; Ribera JM; Gómez-Espuch J; Feliu E
Med Clin (Barc); 1996 Jun; 107(3):118-9. PubMed ID: 8754503
[No Abstract] [Full Text] [Related]
55. [Study of optimal CHOP dose ranges for elderly patients with non-Hodgkin's lymphoma].
Mori M; Murai Y; Suzuki K; Nonaka Y; Sato H; Tomiyama J; Takagi T; Muto Y; Kashimura M
Rinsho Ketsueki; 1999 Mar; 40(3):199-204. PubMed ID: 10222626
[TBL] [Abstract][Full Text] [Related]
56. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
[TBL] [Abstract][Full Text] [Related]
57. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
Jacobson JO; Grossbard M; Shulman LN; Neuberg D
Clin Lymphoma; 2000 Dec; 1(3):211-7; discussion 218. PubMed ID: 11707832
[TBL] [Abstract][Full Text] [Related]
58. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
[TBL] [Abstract][Full Text] [Related]
59. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
[TBL] [Abstract][Full Text] [Related]
60. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
